The FDA plans to change its requirements for Phase 3 clinical trials, shifting from a default of two pivotal trials to one. This move aims to streamline the drug development process, which currently costs pharmaceutical companies an average of $2.6 billion and takes 10 to 15 years from discovery to approval. While some drugs may still need two trials based on the disease they target, biotech experts believe this change could significantly reduce time and costs for many companies, especially smaller ones with limited resources. Experts highlight that the rule change won't impact all drugs equally. For diseases like ALS, where urgency is critical, conducting only one trial could expedite the availability of treatments. However, for conditions with high placebo rates, such as pain, proving efficacy with just one study may prove challenging. Smaller biotech firms stand to benefit the most, as they often juggle multiple drug developments but have limited funding. Reducing clinical trial requirements could allow them to bring more products to market without sacrificing quality. Concerns about safety remain prominent. Experts are reassured by the FDA's continued commitment to postmarket surveillance and advancements in technology, such as AI and real-world data, that can enhance trial precision. Active communication between biotechs and the FDA will be essential to navigating these changes effectively. It's clear that while the rule change offers potential benefits, it also requires careful consideration of safety and efficacy standards.